Skip to main content
Signal8
Launch Terminal

Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Damora Therapeutics, Inc. Ordinary Shares logo

Damora Therapeutics, Inc. Ordinary Shares

NASDAQ:DMRAHealthcare
-2.36%$21.49
AH$21.49+0.00%vs close
Mkt Cap$1.33B
Float45.93M
O/S61.74M
Vol
$ Vol
RVOL
Inst Own-
SI11.2%
Earnings
Dilution
Damora Therapeutics, Inc. Ordinary Shares logoNASDAQ:DMRA$21.49-2.36%
Phase Distribution
10 lead-sponsored trials·2 active·4 completed
Phase 14
Phase 1/24
Phase 22
(1 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting1
Completed4
Stopped2
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

    GB0139, Placebo

    Idiopathic Pulmonary Fibrosis (IPF)

    Enrollment
    172
    Start
    Feb 2019
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT03832946
  • Phase 2
    Active, not recruiting

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

    GB2064

    Myelofibrosis

    Enrollment
    21
    Start
    Jun 2021
    Primary Completion
    Dec 2023
    Completion
    Jun 2026est.
    NCT04679870
  • Phase 1/2
    Completed

    RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients

    Inhaled TD139, Placebo

    Idiopathic Pulmonary Fibrosis

    Enrollment
    60
    Start
    Sep 2014
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02257177
  • Phase 1/2
    Withdrawn

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

    GB1211, Placebo

    Non-alcoholic Steatohepatitis (NASH)

    Enrollment
    0
    Start
    Mar 2021est.
    Primary Completion
    Jul 2022est.
    Completion
    Jul 2022est.
    NCT04607655
  • Phase 1/2
    Unknown status

    A Single and Repeat Dose Trial in Participants With Hepatic Impairment

    GB1211, Placebo

    Hepatic Impairment

    Enrollment
    54
    Start
    Sep 2021
    Primary Completion
    Jul 2022
    Completion
    Jul 2023est.
    NCT05009680
  • Phase 1/2
    Unknown status

    A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

    GB1211, Placebo

    Non-Small Cell Lung Cancer

    Enrollment
    88
    Start
    Mar 2022
    Primary Completion
    May 2024est.
    Completion
    Nov 2025est.
    NCT05240131
  • Phase 1
    Completed

    A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects

    GB1211, Placebo

    Safety and Tolerability

    Enrollment
    78
    Start
    Jan 2019
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT03809052
  • Phase 1
    Completed

    A Study to Compare Pharmacokinetics of GB1211

    GB1211

    Pharmacokinetics

    Enrollment
    13
    Start
    Jan 2023
    Primary Completion
    Apr 2023
    Completion
    Apr 2023
    NCT05747573
  • Phase 1
    Withdrawn

    ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    GB3226

    Relapsed/Refractory Acute Myeloid Leukemia (AML)

    Enrollment
    0
    Start
    Jun 2026est.
    Primary Completion
    Jun 2029est.
    Completion
    Oct 2029est.
    NCT07084584
  • Phase 1
    Recruiting

    A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

    DMR-001, Ruxolitinib

    Myeloproliferative Neoplasms (MPNs)

    Enrollment
    250
    Start
    Sep 2026est.
    Primary Completion
    Jun 2030est.
    Completion
    Jun 2030est.
    NCT07849231
Search ClinicalTrials.gov for “Damora Therapeutics”